ATE259826T1 - Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase - Google Patents

Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase

Info

Publication number
ATE259826T1
ATE259826T1 AT99914958T AT99914958T ATE259826T1 AT E259826 T1 ATE259826 T1 AT E259826T1 AT 99914958 T AT99914958 T AT 99914958T AT 99914958 T AT99914958 T AT 99914958T AT E259826 T1 ATE259826 T1 AT E259826T1
Authority
AT
Austria
Prior art keywords
side chain
transferase inhibitors
farnesyl transferase
functionalized alkyl
alkenyl side
Prior art date
Application number
AT99914958T
Other languages
English (en)
Inventor
Annette Marian Doherty
James Stanley Kaltenbronn
Daniele Marie Leonard
Dennis Joseph Mcnamara
John Quin Iii
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE259826T1 publication Critical patent/ATE259826T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99914958T 1998-04-27 1999-03-19 Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase ATE259826T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8325598P 1998-04-27 1998-04-27
PCT/US1999/006090 WO1999055725A1 (en) 1998-04-27 1999-03-19 Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors

Publications (1)

Publication Number Publication Date
ATE259826T1 true ATE259826T1 (de) 2004-03-15

Family

ID=22177160

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99914958T ATE259826T1 (de) 1998-04-27 1999-03-19 Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase

Country Status (15)

Country Link
US (1) US6369034B1 (de)
EP (1) EP1076663B1 (de)
JP (1) JP2002513031A (de)
KR (1) KR20010043035A (de)
AT (1) ATE259826T1 (de)
AU (1) AU759492B2 (de)
BR (1) BR9909961A (de)
CA (1) CA2322944C (de)
DE (1) DE69914893T2 (de)
DK (1) DK1076663T3 (de)
ES (1) ES2214021T3 (de)
NZ (1) NZ507165A (de)
PT (1) PT1076663E (de)
WO (1) WO1999055725A1 (de)
ZA (1) ZA200006035B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2478500A (en) 1998-12-08 2000-06-26 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040265315A1 (en) * 2002-09-05 2004-12-30 Christine Dingivan Methods of preventing or treating T cell malignancies by administering CD2 antagonists
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
JP3837633B2 (ja) * 2002-11-19 2006-10-25 株式会社クレディアジャパン 新規な機能性ペプチド核酸およびその製法
EP1613273B1 (de) 2003-04-11 2012-06-13 MedImmune, LLC Rekombinante il-9-antikörper und ihre verwendung
DE10326303A1 (de) * 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1660186B1 (de) 2003-08-18 2013-12-25 MedImmune, LLC Humanisierung von antikörpern
EP2422811A2 (de) 2004-10-27 2012-02-29 MedImmune, LLC Modulation von Antikörperspezifität mittels Anpassung der Affinität zu verwandten Antigenen
EP1869192B1 (de) 2005-03-18 2016-01-20 MedImmune, LLC Rahmenmischung von antikörpern
US8987306B2 (en) * 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
AU2006254936A1 (en) * 2005-06-07 2006-12-14 The Trustees Of The University Of Pennesylvania Inhibitors of the alpha2beta1/GPIa-IIa integrin
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
WO2007027742A2 (en) * 2005-08-31 2007-03-08 The Trustees Of The University Of Pennsylvania SMALL MOLECULE INTEGRIN α2βl/GPIa-IIa ANTAGONISTS
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
MX2010004374A (es) 2007-10-31 2010-04-30 Medimmune Llc Armazones proteinicos.
AR085091A1 (es) 2011-01-26 2013-09-11 Kolltan Pharmaceuticals Inc Anticuerpos anti-kit y sus usos
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
CA2887129A1 (en) 2012-10-09 2014-04-17 Igenica, Inc. Anti-c16orf54 antibodies and methods of use thereof
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2950602C (en) 2014-06-04 2021-07-20 MabVax Therapeutics, Inc. Human monoclonal antibodies to ganglioside gd2
CA2970352A1 (en) 2014-12-11 2016-06-16 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
HRP20230046T1 (hr) 2015-03-03 2023-03-03 Kymab Limited Protutijela, upotreba i postupci
US11253590B2 (en) 2015-12-02 2022-02-22 Stsciences, Inc. Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
WO2018222689A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
CN121609797A (zh) 2017-06-06 2026-03-06 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
EP3694889A1 (de) 2017-10-13 2020-08-19 Boehringer Ingelheim International GmbH Humane antikörper gegen thomsen-nouvelle (tn)-antigen
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
US20230271917A1 (en) * 2020-07-22 2023-08-31 Fog Pharmaceuticals, Inc. Amino acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2172125A1 (en) 1993-09-30 1995-04-06 S. Jane Desolms Inhibitors of farnesyl-protein transferase
EP0730605A1 (de) * 1993-11-05 1996-09-11 Warner-Lambert Company Substituierte di- und tripeptide mit protein: farnesyl transferase inhibierende aktivität
US5571792A (en) * 1994-06-30 1996-11-05 Warner-Lambert Company Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
IL126833A0 (en) * 1996-05-22 1999-08-17 Warner Lambert Co Inhibitors of protein farnesyl transferase
NZ334702A (en) * 1996-12-17 2000-11-24 Warner Lambert Co Cycloalkyl inhibitors of protein farnesyltransferase
US6265382B1 (en) * 1997-04-11 2001-07-24 Warner-Lambert Company Dipeptide inhibitors of protein farnesyltransferase

Also Published As

Publication number Publication date
US6369034B1 (en) 2002-04-09
AU759492B2 (en) 2003-04-17
NZ507165A (en) 2003-06-30
JP2002513031A (ja) 2002-05-08
DE69914893D1 (de) 2004-03-25
EP1076663A1 (de) 2001-02-21
AU3358799A (en) 1999-11-16
CA2322944C (en) 2003-05-20
ZA200006035B (en) 2002-01-28
DE69914893T2 (de) 2004-07-22
PT1076663E (pt) 2004-06-30
CA2322944A1 (en) 1999-11-04
EP1076663B1 (de) 2004-02-18
KR20010043035A (ko) 2001-05-25
BR9909961A (pt) 2000-12-26
ES2214021T3 (es) 2004-09-01
WO1999055725A1 (en) 1999-11-04
DK1076663T3 (da) 2004-06-01

Similar Documents

Publication Publication Date Title
ATE259826T1 (de) Glycinamidederivate mit funktionalisierter alkyl- und alkenylseitenkette als inhibitoren der farnesyltransferase
ATE307119T1 (de) Bicyclische protein-farnesyl-transferase inhibitoren
DE69432614D1 (de) Alkohol und Aldehyde Derivate als Cathepsin L Inhibitore und als Inhibitore der Knochenresorption
ES2130930A1 (es) Recubrimientos y materiales de registro estabilizados con absorbentes de ultravioleta de benzotriazol.
IS6309A (is) Kínasólínafleiður
ATE430563T1 (de) Cyano-substituierte oleanolsäure als inhibitor der no-produktion
FI973217A0 (fi) Heteroaromaattisella renkaalla substituoituja antimikrobiaalisia fenyylioksatsolidinoniyhdisteitä
LV12712A (lv) Inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodekstrin and method
ATE263771T1 (de) Totalsynthese von acylfulvenen mit antitumorwirkung
DK1000034T3 (da) Substituerede 6-alkylphenanthridiner
ATE248814T1 (de) 16-ene-vitamin d derivate
EP0753511A4 (de) Indol-derivate und diese enthaltende arzneimittel
DK0668279T3 (da) 6-azaindol thromboxansytaseinhibitor
FI945290A0 (fi) Menetelmä ribonukleotidireduktaasi-inhibiittoreiden valmistamista varten
ATE265854T1 (de) Azasteroidverbindung zur behandlung oder vorbeugung von prostatakrebs
NO20004477D0 (no) Anvendelse av organiske karbonater som løsningsmidler for vasking av metalloverflater
BR9908905A (pt) Novos compostos
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1076663

Country of ref document: EP

REN Ceased due to non-payment of the annual fee